LobbyingBrownstein Hyatt Farber Schreck LLP Obo Romark Global Pharma lobbying by quarter
Brownstein Hyatt Farber Schreck LLP Obo Romark Global Pharma's latest lobbying report covers Q2 2023, at under $5,000. Its first report covers Q4 2022; the issues it reports most are Pharmacy.
Brownstein Hyatt Farber Schreck LLP Obo Romark Global Pharma
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
No lobbying spend in this period.
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $0 | 1 |
| Q1 2023 | $0 | 1 |
| Q2 2023 | $0 | 1 |
| Q3 2023 | $0 | 0 |
| Q4 2023 | $0 | 0 |
| Q1 2024 | $0 | 0 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Pharmacy$0 · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- SENATE1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Northern Compass Group | $0 | 3 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| MARK BEGICH | Former Senator, U.S. Senate | Q4 2022 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 23/07/19for Q2 2023 | Northern Compass Group | Under $5,000 |
| 23/04/18for Q1 2023 | Northern Compass Group | Under $5,000 |
| 23/01/19for Q4 2022 | Northern Compass Group | Under $5,000 |
| 23/01/18for Q4 2022 | Northern Compass Group | Under $5,000 |